Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Espindolol - Actimed Therapeutics

Next Previous
Search
Drug Profile

Espindolol - Actimed Therapeutics

Alternative Names: ACM 001; ACM-001.1; MT-102; S-pindolol; S-pindolol benzoate

Latest Information Update: 12 Feb 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PsiOxus Therapeutics
  • Developer Actimed Therapeutics; Akamis Bio
  • Class Irritable bowel syndrome therapies; Small molecules
  • Mechanism of Action 5-HT1A serotonin receptor antagonists; Beta adrenergic receptor agonists; Beta adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cachexia
  • Discontinued Sarcopenia

Most Recent Events

  • 06 Feb 2025 Actimed Therapeutics received two new composition of matter patents granted in the US and Europe
  • 28 Jan 2025 No recent reports of development identified for clinical-Phase-Unknown development in Cachexia(In volunteers) in United Kingdom (PO, Tablet)
  • 13 Dec 2024 Pharmacodynamics, pharmacokinetics and adverse event data from a phase I trial in Cachexia released by Actimed Therapeutics

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top